{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:30:53Z","timestamp":1791192653965,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,11]]},"abstract":"ABSTRACT<\/jats:title>\n \n Infections with\n Corynebacterium striatum<\/jats:named-content>\n have been described in the literature over the last 2 decades, with the majority being bacteremia, central line infections, and occasionally, endocarditis. In recent years, the frequency of\n C. striatum<\/jats:named-content>\n infections appears to be increasing; a factor likely contributing to this is the increased ease and accuracy of the identification of\n Corynebacterium<\/jats:named-content>\n spp., including\n C. striatum<\/jats:named-content>\n , from clinical cultures. The objective of this study was to retrospectively characterize\n C. striatum<\/jats:named-content>\n isolates recovered from specimens submitted as part of routine patient care at a 1,250-bed, tertiary-care academic medical center. Multiple strain types were recovered, as demonstrated by repetitive-sequence-based PCR. Most of the strains of\n C. striatum<\/jats:named-content>\n characterized were resistant to antimicrobials commonly used to treat Gram-positive organisms, such as penicillin, ceftriaxone, meropenem, clindamycin, and tetracycline. The MIC\n 50<\/jats:sub>\n for ceftaroline was >32 \u03bcg\/ml. Although there are no interpretive criteria for susceptibility with telavancin, it appeared to have potent\n in vitro<\/jats:italic>\n efficacy against this species, with MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n values of 0.064 and 0.125 \u03bcg\/ml, respectively. Finally, as previously reported in case studies, we demonstrated rapid\n in vitro<\/jats:italic>\n development of daptomycin resistance in 100% of the isolates tested (\n n<\/jats:italic>\n = 50), indicating that caution should be exhibited when using daptomycin for the treatment of\n C. striatum<\/jats:named-content>\n infections.\n C. striatum<\/jats:named-content>\n is an emerging, multidrug-resistant pathogen that can be associated with a variety of infection types.\n <\/jats:p>","DOI":"10.1128\/aac.01111-17","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T20:30:26Z","timestamp":1503952226000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":98,"title":["When Good Bugs Go Bad: Epidemiology and Antimicrobial Resistance Profiles of Corynebacterium striatum, an Emerging Multidrug-Resistant, Opportunistic Pathogen"],"prefix":"10.1128","volume":"61","author":[{"given":"Allison R.","family":"McMullen","sequence":"first","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan A.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Shupe","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-840X","authenticated-orcid":false,"given":"Carey-Ann D.","family":"Burnham","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.07.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1805-5"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.045"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13786"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00925-16"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12171"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.3.576"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0927"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1501.080804"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2008.08.009"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01532-10"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.06.001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12223-013-0227-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-014-0844-1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2015.35.4.472"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2188-6"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2010.05.018"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-12-52"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/genomeA.00869-15"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760140373"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.7577"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0208"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2211.160141"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2015.07.007"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00450-08"},{"key":"e_1_3_2_27_2","volume-title":"CLSI guideline M45","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria,3rd ed. CLSI guideline M45. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"3"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762013000100004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1099\/00207713-50-1-347"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06439-11"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00386-12"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.11.001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.10.004"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.019"},{"key":"e_1_3_2_35_2","volume-title":"CLSI supplement M100","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. Performance standards for antimicrobial susceptibility testing,27th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"27"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-1128-3"},{"key":"e_1_3_2_37_2","volume-title":"CLSI document M45-A2","author":"CLSI","year":"2010","unstructured":"CLSI. 2010. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline,2nd ed. CLSI document M45-A2. Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"2"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.07.013"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01111-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01111-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:41:17Z","timestamp":1645458077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01111-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1128\/AAC.01111-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01111-17","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.729805204.793538585","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01111-17"}}